Abstracts tagged "Mortality"

Abstract Number: 1187 • ACR Convergence 2025
Myositis-Specific Antibody Profiles and Factors Associated With Rapidly Progressive Interstitial Lung Disease and Mortality in Antisynthetase Syndrome: A Systematic Review and Meta-Analysis
Tulaton Sodsri¹, Nattanicha Chaisrimaneepan², Ben Thiravetyan³, Rabhas Boonyawairote⁴, Nopavit Mohpichai⁵, Nutchapon Xanthavanij⁶, Natnicha Jakramonpreeya⁷, Pintip Ngamjanyaporn⁸ and Tananchai Petnak⁸, ¹Department of Medicine, Texas Tech University Health Sciences Center, Bangkok, Thailand, ²Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ³Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, ⁴University of Illinois at Chicago, Chicago, ⁵Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁶Mount Auburn Hospital, Harvard Medical School, Cambridge, ⁷Chakri Naruebodindra Medical Institute, Bangkok, Thailand, ⁸Ramathibodi Hospital, Bangkok, Thailand
Background/Purpose: The associations between various myositis-specific antibodies (MSAs), rapidly progressive interstitial lung disease (RP-ILD), and mortality in antisynthetase syndrome (ASS) have been previously reported in…
Abstract Number: 0806 • ACR Convergence 2025
Comparative Risk of Infection-Related Complications in Systemic Lupus Erythematosus Patients Treated with Anifrolumab versus Belimumab: A Target Trial Emulation
Teng-Chieh Hsu¹, An-Ping Huo², Pei-Lun Liao², Pui-Ying Leong² and James Wei³, ¹Wuri Lin Shin Hospital, Taichung, Taiwan (Republic of China), ²Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ³Chung Shan Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China)
Background/Purpose: Anifrolumab and belimumab are biologic agents approved for systemic lupus erythematosus (SLE), yet their comparative safety profiles, particularly regarding infection risks, remain inadequately characterized…
Abstract Number: 2383 • ACR Convergence 2025
The Age-Adjusted Charlson Comorbidity Index (CCI) Predicts All-Cause Mortality in Systemic Lupus Erythematosus (SLE) Patients: Data from the Almenara Lupus Cohort
Benny Rashuamán-Conche¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Cristina Reategui-Sokolova⁴, Claudia Elera-Fitzcarrald⁴, Cesar Pastor-Asurza⁵, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁷, Graciela Alarcón⁸ and Manuel Ugarte-Gil⁹, ¹Hospital Guillermo Almenara Irigoyen, Lima, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁶Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁷Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁸The University of Alabama at Birmingham, Oakland, CA, ⁹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru
Background/Purpose: The CCI has been associated with adverse health-related outcomes in SLE-patients worldwide. Its modified version, the age-adjusted CCI (ACCI) has been associated with organ…
Abstract Number: 1880 • ACR Convergence 2025
Rheumatoid Arthritis Mortality in the U.S. (1999–2020): A Decline in Rates, But Not in Disparities
Aziz-ur-Rahman Khalid¹, Ghassan Makhoul², Hasan Munshi², Islam Rajab², Emmanuel Olumuyide³, MD Walid Akram Hussain², Aqsa Sorathia², Elvira Assaf², Amer Al Badawy², John Salama² and Robert Lahita⁴, ¹St. Joseph's University Medical Center, wayne, ²St. Josephs University Medical Center, Paterson, ³Advocate Illinois Masonic Medical Center, Chicago, ⁴St. Josephs University Medical Center, Wayne, NJ
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease associated with increased morbidity and mortality. While treatments have evolved, national trends and sociodemographic disparities in…
Abstract Number: 1143 • ACR Convergence 2025
Gout and Renal Failure-Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
Shiamak Cooper¹, Sanjana Thimmannagari², Ranjini Vengilote² and Asim Khanfar², ¹Rochester General Hospital, Irondequoit, NY, ²Rochester General Hospital, Rochester, NY
Background/Purpose: Gout is the most common form of inflammatory arthropathy, with a prevalence ranging from 0.1% to approximately 10% worldwide. Despite a well-established association between…
Abstract Number: 0746 • ACR Convergence 2025
Impact of Frailty on Mortality in GCA and PMR: A Retrospective Cohort
Fatima Hassan¹, Michael Putman² and Sebastian E Sattui³, ¹Medical College of Wisconsin, Menomonee Falls, WI, ²The Medical College of Wisconsin, Milwaukee, WI, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Frailty, a syndrome associated with decreased physiologic reserve, is associated with adverse outcomes. The prevalence and impact of baseline frailty on the risk of…
Abstract Number: 2382 • ACR Convergence 2025
Autoimmune Hemolytic Anemia in SLE: A Real-World National Cohort Study
Bana Shawareb¹, Muhannad Haddadin¹, lindsay Frumker², Keri Ann Pfeil³, Meghan Gump³, Ansaam Daoud⁴ and Omer Pamuk⁵, ¹Cleveland Clinic Akron General, Akron, OH, ²Case Western Reserve University, Cleveland, ³University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ⁴Case Western Reserve University/University Hospitals, Cleveland, OH, ⁵University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Autoimmune hemolytic anemia (AIHA) is a rare but serious hematologic manifestation of SLE. The prognostic implications of AIHA, particularly long-term mortality and organ involvement,…
Abstract Number: 1879 • ACR Convergence 2025
Infections in Hospitalized Patients With and Without Psoriatic Arthritis (2016–2021): A National Inpatient Sample Study
Ayema Haque, Ana Salas, Bruna Diniz, Harshank Patel and Philip Kroth, Western Michigan University School of Medicine, Kalamazoo, MI
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disorder affecting up to 30% of psoriasis patients and is associated with increased infection risk. This…
Abstract Number: 1087 • ACR Convergence 2025
Impact of Neighborhood-Level Social Vulnerability on Disease Severity, Clinical Manifestations, and Early Mortality in Systemic Lupus Erythematosus
Zoe Reed¹, Catriona Wagner², Xana Howard¹, Alexandre Cammarata-Mouchtouris¹, Study Team ALE⁰⁶ Clinical¹, Wade DeJager³ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with considerable clinical and molecular heterogeneity. Significant disparities exist in SLE, with minority populations experiencing…
Abstract Number: 0462 • ACR Convergence 2025
Does Biological Sex Affect Mortality in Frail Patients with Rheumatoid Arthritis?
Sayuli Bhide¹, Hannah Brubeck², Punyasha Roul³, Aaron Baraff², Bryant England⁴, Nadine El-Ayache¹, Grant Cannon⁵, Namrata Singh⁶, Gary Kunkel⁷, Ted Mikuls⁴, Dolores Shoback⁸, Kaleb Michaud⁴, Patti Katz⁹, Jose Garcia¹⁰, Ariela Orkaby¹¹, Joshua Baker¹² and Katherine Wysham¹³, ¹University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³UNMC, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶University of Washington, Bellevue, WA, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸San Francisco VA Medical Center & University of California San Francisco, San Francisco, CA, ⁹UCSF, San Rafael, CA, ¹⁰VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ¹¹Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Boston, MA, ¹²University of Pennsylvania, Philadelphia, PA, ¹³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Frailty predicts mortality in RA. In the general population, males have a higher risk of death than females despite lower levels of frailty.1 We…
Abstract Number: 2266 • ACR Convergence 2025
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of All-Cause Mortality and All-Cause Cancer: A Population-Based Cohort Study
Mohammad Movahedi¹, Angela Cesta¹, Sibel Aydin², Pooneh Akhavan³, Tetyana Kendzerska⁴, Claire Bombardier¹ and Bindee Kuriya⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³self-employed, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Mississuaga, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Observational studies on RA therapeutic classes have shown conflicting results on their impact on mortality and cancer. When analyzing long-term outcomes, it is essential…
Abstract Number: 1795 • ACR Convergence 2025
Trends and Disparities in Osteoarthritis-Related Mortality in the United States: A 21-Year Analysis (1999-2020)
muzamil Khan¹, Swetha Balaji², Ayesha Cheema³, Wajdan Ahmad³, Dhruv gandhi⁴ and Steven Golombek⁵, ¹George Washington University School of Medicine and Health Sciences, Washington D.C, ²New York Medical College at St. Mary's General Hospital and St. Clare's Health, Parsippany-Troy Hills, NJ, ³Al Tibri Medical College, Karachi, Pakistan, ⁴St. Francis Medical Center, Monroe, ⁵NYMC at St. Mary's General Hospital and St. Clare's Health, Dover
Background/Purpose: Osteoarthritis/arthrosis is an aging-related disease which is associated with significant morbidity in the United States. However, epidemiological data regarding osteoarthritis-associated mortality in the United…
Abstract Number: 1063 • ACR Convergence 2025
Gender, Racial, and Geographic Trends in Mortality from Interstitial Lung Diseases Among Patients With Rheumatoid Arthritis in the U.S. Population, 1999–2020
Farheen Malik¹, Jawad Ahmed², Mandar Shah¹, Ritika Uttam³ and Muhammad Fahimuddin¹, ¹Jacobi Medical Center, Bronx, NY, NY, ²Northwest Health Porter, Valpraiso, IN, ³Jacobi Medical Center, Bronx, NY
Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease affecting up to 1.0% of the US population. RA is most commonly associated with synovial inflammation…
Abstract Number: 0456 • ACR Convergence 2025
Impact of Rheumatoid Arthritis on mortality and other outcomes in Heart failure: A nationwide analysis.
Nisha Sapkota¹, Samuel Sule-saa¹, Yubraj Aryal², Mark Ntow³, Karuna Bista⁴, Parvathy Rajeev³, jemima Alemonai³, Esther Duodu⁵, Brijesh Ghimire³, Pyae Hein³, Jeffrey Sackey⁶, Muhanned Towfig³, Robert Lamptey³, Temesgen Gobena⁷, Daniel Pinkrah⁷ and Mona Pervil Ulysse⁸, ¹Interfaith Medical Center, One Broolyn Health, Brooklyn, NY, ²Geisinger Medical Center, Danville, PA, ³Interfaith Medical Center, One Broolyn Health, Brooklyn, ⁴Montefiore New Rochelle Hospital, New Rochelle, NY, ⁵Broodale Hospital Medical Center, One Broolyn Health, Brooklyn, ⁶Interfaith Medical Center,One Broolyn Health, Brooklyn, ⁷Interfaith Medical Center, Brooklyn, NY, ⁸Interfaith Medical Center, One Brooklyn Health, Brooklyn
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with systemic inflammation and increased cardiovascular risk, particularly heart failure (HF). Patients with RA and…
Abstract Number: 2251 • ACR Convergence 2025
Dual Diagnoses, Diminished Survival: Association between rheumatoid arthritis and survival among older adults with lung cancer
Michelle Nguyen¹, Aaron Baraff², Alexandra Schmidt², Alexander Peterson², Aliyah Pabani³, Nicholas Smith¹, Shelly Gray¹, Jose Garcia⁴, Noel Weiss¹ and Namrata Singh⁵, ¹University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³Johns Hopkins, Washington, DC, ⁴VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ⁵University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of malignancies, particularly lung cancer, relative to the general population1. However, the association between RA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].